Scholar Rock, a spinal muscular atrophy therapy developer backed by Kraft Group, floated in the middle of its range.
Scholar Rock, the US-based spinal muscular atrophy (SMA) treatment developer that counts conglomerate Kraft Group as an investor, has raised approximately $75m in its initial public offering.
The company issued almost 5.4 million shares on the Nasdaq Global Select Market priced at $14.00, the midpoint of the IPO’s $13 to $15 range. It floated last week and its shares are currently at $16.12 at time of publication.
Scholar Rock is working on therapies for conditions in which signalling by…
